Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome
2007-000969-37Phase 2Terminated
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of varespladib in acute chest syndrome (ACS), sickle cell disease (SCD) and vaso-occlusive crisis (VOC), sponsored by Anthera Pharmaceuticals, Inc. Primary endpoint: Safety and tolerability of A-001 in SCD patients with VOC. Started Mar 2007; status: terminated.
02
Drugs
varespladib
03
Conditions
acute chest syndrome (ACS)sickle cell disease (SCD)vaso-occlusive crisis (VOC)
Beyond the preview
Go deeper on 2007-000969-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000969-37.